A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide
3-kinase (p110α). The purpose of this study is to assess the safety, tolerability,
pharmacokinetics (PK), and efficacy of HS-10352 plus fulvestrant in patients with hormone
receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast
cancer (ABC) harboring PIK3CA mutations.